Luna Innovations Incorporated (NASDAQ: LUNA), a company focusing on
sensing & instrumentation and pharmaceutical nanomedicines,
today announced its financial results for the third quarter ended
September 30, 2008. Kent Murphy, Chairman and Chief Executive
Officer, provided this overview of Luna�s results: �I am pleased to
report that during the third quarter we continued to achieve our
planned improvement in both revenue and bottom line results. For
the first time, we achieved quarterly revenue in excess of $10
million. Our revenues of $10.7 million in the third quarter of 2008
represent an increase of 21% as compared to the same quarter last
year, with growth of more than 20% in both of our lines of
business. Our gross profit increased from $3.5 million in the third
quarter of 2007 to $4.3 million this past quarter, and due in part
to our continued focus on our operating expenses, our loss per
share declined from $0.18 to $0.04. Excluding a one-time benefit
that we realized on a litigation settlement with our former
auditors, our net loss per share would have been $0.10, which is a
substantial improvement compared to the third quarter of 2007. �Our
higher-margin product and license revenues continue to grow, and we
remain on track to achieve a growth of approximately 30% in that
segment this year as compared to last year. We also had continued
success in strengthening our Technology Development Division and
have a solid backlog of contracts specifically supporting much of
our product development efforts. �Also during the past quarter, we
announced a National Institutes of Health grant from the National
Cancer Institute to develop a contrast agent that is targeted to
image brain cancers. Under this program, Luna is tasked with
producing an improved magnetic resonance imaging (MRI) agent to
enhance tumor imaging and advance the diagnosis and treatment of
this disease by directing nanomolecules to specific biological
targets. We expect that our exclusive nanotechnology using carbon
nanospheres can meet the needs of this program.� Third Quarter
Financial Highlights -- Achieved quarterly revenue greater than $10
million. Total revenues for the third quarter of 2008 increased 21%
compared to the third quarter of 2007. -- Product and license
revenues grew 21% to approximately $3.5 million in the third
quarter of 2008, compared to $2.9 million in the third quarter of
2007. -- Gross profit for the third quarter of 2008 increased 21%
to $4.3 million from $3.5 million for the corresponding period of
2007. -- Operating expenses decreased 3% to $5.4 million, or 50% of
total revenues, from $5.5 million, or 63% of total revenues, in the
third quarter of 2007. -- Net loss improved to $0.5 million from
$1.8 million in the third quarter of 2007. Excluding the one-time
benefit from a July 2008 settlement of a dispute with our former
auditing firm the net loss would have been $1.1 million. -- Net
loss per share for the third quarter of 2008 was $0.04 per share.
Excluding the non-recurring, non-operating income related to the
July 2008 settlement, net loss per share for the third quarter of
2008 would have been $0.10 per share compared to a net loss per
share of $0.18 in the third quarter of 2007. -- Cash and cash
equivalents totaled $15.2 million at September 30, 2008, as
compared to $15.3 million at June 30, 2008, and $12.0 million at
December 31, 2007. Third Quarter Business Highlights -- Awarded a
grant from the National Cancer Institute to adapt Luna�s exclusive
carbon nanosphere-based contrast agent technology to produce an
improved MRI agent for enhanced tumor imaging and advanced
diagnosis and treatment. -- Continued to meet the development
objectives and timeline of our partnership with Intuitive Surgical,
Inc. to adapt Luna�s shape sensing technology for use in medical
robotics for minimally invasive surgery. -- Demonstrated an
increase in the number of hair follicles and growth of new hair on
a second species of mouse using a topical application of our
proprietary nanomedical compound; identified the lead compound for
future development efforts of this potential product. -- Realized
20% increase in organic solar cell overall efficiency based upon
the increase in open circuit voltage obtained from using Luna�s
exclusive TRIMETASPHERE� in place of the empty cage fullerenes
typically used today. Outlook for Remainder of 2008 For the fourth
quarter of 2008, the company currently anticipates continued
year-over-year growth in both its product and license segment and
its Technology Development Division. The company currently expects
total revenue to be in the range of $40.0 million to $41.0 million
for 2008. Also for 2008, the company anticipates a net loss in the
range of $6.0 million to $6.5 million. The improvement in expected
net loss for the year from our earlier guidance of $6.5 million to
$7.0 million reflects the non-recurring benefit realized from the
July 2008 settlement. Accordingly, for the fourth quarter of 2008,
the company expects revenue of approximately $10.5 million to $11.5
million and a net loss of approximately $1.8 million to $2.3
million. The higher expected loss in the fourth quarter of 2008
compared to the current quarter is primarily attributable to the
expected increase in costs related to on-going litigation with
Hansen Medical as Luna progresses toward trial in that matter.
Conference Call Information As previously announced, Luna
Innovations will conduct an investor conference call at 11:00 a.m.
(EST) today to discuss its financial results, business developments
and expectations for 2008. The call can be accessed by dialing
1.866.202.1971 domestically or 1.617.213.8842 internationally prior
to the start of the call. The access code is 48200647. The
conference call will also be webcast live over the Internet. The
webcast can be accessed by logging on to the �Investor Relations�
section of the Luna Innovations Web site,
http://www.lunainnovations.com, prior to the event. The webcast
will be archived under the �Webcasts and Presentations� section of
the Luna Innovations Web site for at least 30 days following the
conference call. About Luna Innovations: Luna Innovations
Incorporated (www.lunainnovations.com) develops and manufactures
new-generation products for the healthcare, telecommunications,
energy and defense markets. Our products are used to measure,
monitor, protect and improve critical processes in the markets we
serve. Through its disciplined commercialization business model,
Luna has become a recognized leader in transitioning science to
solutions. Luna is headquartered in Roanoke, Virginia. Forward
Looking Statements: This release includes information that
constitutes �forward-looking statements� made pursuant to the safe
harbor provisions of Section�27A of the Securities Act of 1933 and
Section�21E of the Securities Exchange Act of 1934, including
statements regarding, but not limited to: (i) the company�s ability
to successfully develop an improved magnetic resonance imaging, or
MRI, contrast agent pursuant to its grant from the National Cancer
Institute, (ii) the company�s ability to successfully obtain
regulatory approval and to sell an improved MRI contrast agent,
(iii) the company�s anticipated growth in its product and license
and technology development divisions in 2008 and increased revenues
in those areas, (iv) the company�s continued success and
profitability from its partnership with Intuitive Surgical, Inc.,
(v) the company�s expectations regarding future products and
revenues that may be generated from its research in new
technologies, including hair growth and solar cell applications of
its nanotechnology, (vi) the company�s expectations with respect to
the resolution of litigation with Hansen Medical; and (vii) the
company�s financial outlook for its fourth quarter 2008 and full
fiscal year 2008, including expected revenues and net loss as well
as the underlying growth rates assumptions and expected components
thereof. The company attempts, whenever possible, to identify
forward-looking statements by words such as �intends,� �will,�
�plans,� �anticipates,� �expects,� �may,� �estimates,� �believes,�
�should,� �projects,� or �continue,� or the negative of those words
and other comparable words. Similarly, statements that describe the
company�s business strategy, goals, prospects, opportunities,
outlook, objectives, plans or intentions are also forward-looking
statements. Actual events or results may differ materially from the
expectations expressed in such forward-looking statements as a
result of various factors, including risks and uncertainties, many
of which are beyond the company�s control. Factors that could cause
actual results to differ materially from the expectations expressed
in such forward-looking statements include, but are not limited to:
the company�s ability to manage its growth effectively; the
company�s ability to transition its revenue mix to product revenues
and the company�s limited experience in manufacturing products on a
commercial scale; the company�s ability to successfully identify
market needs for new products; the company�s ability to attract
skilled employees; the company�s continued reliance on contract
research, including government grants and contracts available only
to small businesses, for a significant portion of its revenue; the
company�s ability to remain eligible for small business government
grants and contracts in the future; the company�s ability to
maintain sufficient proprietary rights to protect its technologies;
the potential adverse effects of nanotechnology, whether real or
perceived; the potential limitations of regulatory requirements in
obtaining clearance by the U.S. Food and Drug Administration or
other regulatory agencies for the company�s products; and risks
inherent in current or future litigation proceedings. Additional
factors that may affect the future results of the company are set
forth in the company�s quarterly and annual reports on Form 10-Q
and Form 10-K, respectively, and other filings with the Securities
and Exchange Commission (�SEC�), which are available at the SEC�s
website at http://www.sec.gov, and at the company�s website at
http://www.lunainnovations.com. These risk factors are updated from
time to time through the filing of periodic reports with the SEC.
The statements made in this press release are based on information
available to the company as of the date of this release and Luna
Innovations undertakes no obligation to update any of the
forward-looking statements herein after the date of this press
release. � Luna Innovations Incorporated Consolidated Statements of
Operations � � � � � � � Three Months Ended Nine Months Ended
September 30, September 30, � 2008 � � 2007 � � 2008 � � 2007 �
(unaudited) (unaudited) (unaudited) (unaudited) Revenues: Contract
research revenues $ 7,246,674 $ 5,952,747 $ 20,795,697 $ 17,091,452
Product and license revenues � 3,456,872 � � 2,867,453 � �
8,706,075 � � 6,654,200 � Total revenues 10,703,546 8,820,200
29,501,772 23,745,652 Cost of revenues: Contract research costs
4,983,336 4,008,829 13,558,984 11,929,264 Product and license costs
� 1,453,467 � � 1,281,367 � � 4,222,699 � � 2,670,916 � Total cost
of revenues � 6,436,803 � � 5,290,196 � � 17,781,683 � � 14,600,180
� Gross profit 4,266,743 3,530,004 11,720,089 9,145,472 Operating
expense � 5,371,530 � � 5,511,561 � � 16,466,299 � � 16,182,168 �
Operating loss � (1,104,787 ) � (1,981,557 ) � (4,746,210 ) �
(7,036,696 ) Other income (expense) Other income 667,125 49,515
667,125 47,904 Interest income, net � (36,323 ) � 93,690 � �
(45,345 ) � 290,571 � Total other income � 630,802 � � 143,205 � �
621,780 � � 338,475 � Loss before income taxes (473,985 )
(1,838,352 ) (4,124,430 ) (6,698,221 ) Income tax expense � - � � -
� � - � � - � Net loss $ (473,985 ) $ (1,838,352 ) $ (4,124,430 ) $
(6,698,221 ) Net loss per share: Basic $ (0.04 ) $ (0.18 ) $ (0.38
) $ (0.66 ) Diluted $ (0.04 ) $ (0.18 ) $ (0.38 ) $ (0.66 )
Weighted average shares: Basic � 11,055,613 � � 10,293,557 � �
10,924,596 � � 10,134,313 � Diluted � 11,055,613 � � 10,293,557 � �
10,924,596 � � 10,134,313 � � � Luna Innovations Incorporated
Consolidated Balance Sheets � � � � September 30, December 31, �
2008 � � 2007 � � Assets (unaudited) Current assets Cash and cash
equivalents $ 15,181,265 $ 12,046,945 Accounts receivable, net
10,415,251 9,716,610 Refundable income taxes 390,661 396,062
Inventory 2,291,968 1,675,239 Other current assets � 533,484 � �
333,105 � Total current assets 28,812,629 24,167,961 Property and
equipment, net 5,639,168 5,859,515 Intangible assets, net 1,815,895
1,911,132 Deferred tax asset 600,000 600,000 Other assets � 126,991
� � 10,270 � Total assets $ 36,994,683 � $ 32,548,878 � �
Liabilities and stockholders' equity Current liabilities Current
portion of capital lease obligation $ 21,458 $ 23,885 Current
portion of long-term debt obligation 1,071,429 - Accounts payable
4,235,604 3,024,973 Accrued liabilities 5,244,507 5,331,798
Deferred credits � 1,732,319 � � 1,672,400 � Total current
liabilities 12,305,317 10,053,056 Long-term capital lease
obligation - 4,671 Long-term debt obligation 8,928,571 5,000,000
Deferred credits and other long term liabilities � - � � 354,418 �
Total liabilities � 21,233,888 � � 15,412,145 � Stockholders'
equity: Preferred stock, par value $0.001, 5,000,000 shares
authorized, no shares issued and outstanding - - Common stock, par
value $0.001, 100,000,000 shares authorized, 11,102,365 and
10,704,456 shares issued and outstanding 11,102 10,704 Additional
paid-in capital 37,244,157 34,496,063 Accumulated deficit �
(21,494,464 ) � (17,370,034 ) Total stockholders' equity �
15,760,795 � � 17,136,733 � Total liabilities and stockholders'
equity $ 36,994,683 � $ 32,548,878 � � � Luna Innovations
Incorporated Consolidated Statements of Cash Flows � � � Nine
months ended September 30, � 2008 � � 2007 � (unaudited)
(unaudited) Cash flows used in operating activities Net loss $
(4,124,430 ) $ (6,698,221 ) Adjustments to reconcile net loss to
net cash used in operating activities: Depreciation and
amortization 1,425,857 1,324,155 Share-based compensation 2,163,467
1,722,734 Change in assets and liabilities: Accounts receivable
(698,641 ) (1,546,225 ) Inventory (1,029,786 ) (707,726 ) Other
assets (253,505 ) 128,854 Accounts payable and accrued expenses
1,493,982 1,071,451 Deferred credits � (294,499 ) � 925,875 � Net
cash used in operating activities � (1,317,555 ) � (3,779,103 )
Cash flows used in investing activities Acquisition of property and
equipment (318,436 ) (1,233,932 ) Intangible property costs �
(378,780 ) � (320,110 ) Net cash used in investing activities �
(697,216 ) � (1,554,042 ) Cash flows from financing activities
Proceeds from/ (Payments on) debt obligations 5,000,000 (214,955 )
Payments on capital lease obligations (7,098 ) (63,036 ) Proceeds
from the exercise of options and warrants � 156,189 � � 272,777 �
Net cash used in financing activities � 5,149,091 � � (5,214 ) Net
change in cash 3,134,320 (5,338,359 ) Cash - beginning of period �
12,046,945 � � 17,866,753 � Cash - end of period $ 15,181,265 � $
12,528,394 � � � Luna Innovations Incorporated Reconciliation of
Net Loss and Loss Per Share�Before Litigation Settlement For the
Quarter Ended September 30, 2008 � � Net loss, as reported $
(473,985 ) � Deduct net benefit realized from litigation settlement
proceeds (666,332 ) � Net loss, before litigation settlement $
(1,140,317 ) � � Net loss per share before litigation settlement:
Basic $ (0.10 ) Diluted $ (0.10 ) Weighted average shares: Basic �
11,055,613 � Diluted � 11,055,613 �
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Luna Innovations (NASDAQ:LUNA)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024